PARTNERS

Alliances

Amgen Xencor has entered into an option agreement with Amgen for worldwide rights to XmAb®5871, a monoclonal antibody dually targeting CD19 and CD32b to inhibit autoimmune diseases. Xencor will lead development through the first Phase 2 trial.
janssen_logo Xencor is collaborating with Janssen R&D (formerly Centocor) using Xencor’s Xtend half-life prolongation technology and XmAb® ADCC enhancing technology to optimize performance of the company’s therapeutic monoclonal antibodies.
merck_logo Merck has licensed Xencor XmAb® technology to create enhanced performance in their therapeutic biologic programs.
MorphoSys MorphoSys has licensed worldwide rights for XmAb®5574/MOR208, a B-cell targeting antibody with XmAb® ADCC enhancing technology. Xencor and MorphoSys are collaborating for the clinical development of XmAb5574 in oncology and autoimmune diseases.
Boehringer Ingelheim Xencor is collaborating with Boehringer Ingelheim to create monoclonal antibodies with greatly enhanced potency. Boehringer Ingelheim will use Xencor’s XmAb® engineered Fc’s to improve antibodies against select Boehringer Ingelheim.
CSL Xencor is collaborating with CSL Ltd. to provide access to Xencor’s XmAb® technology platform to enhance the ADCC effector function of its therapeutic antibodies and Xencor’s Xtend Fc domains to enhance the half-life of its therapeutic antibodies.
Alexion Xencor is collaborating with Alexion to create next generation monoclonal antibodies with greatly improved pharmacology. Alexion will use Xencor’s Xtend™ Fc domain to enhance the half-life of its therapeutic antibodies against selected targets.